Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods
Narjess Ayati, Sze Ting Lee, Seyed Rasoul Zakavi, Melissa Cheng, Eddie Lau, Sagun Parakh, Kunthi Pathmaraj, Andrew M. Scott
Abstract
F-FDG-avid lesion according to PERCIST and imPERCIST accurately reflects the overall metabolic response.
Topics & Concepts
ImmunotherapyLung cancerMedicineOncologyInternal medicinePD-L1CancerCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment